Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · The Lancet Oncology · 865 citations
https://doi.org/10.1016/s1470-2045(19)30863-0